LIMN

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

424B3 - Liminatus Pharma, Inc. (0001971387) (Filer)

FULLERTON, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company") today announced that it has entered into a warrant exercise agreement with existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 10,344,000 shares of common stock of the Company (the "Existing Warrants"). In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders were issued new unregistered warrants to purchase an aggregate of 20,688,000 million shares of common stock (the "New Warrants"). In connection with the exercise, the Company also agreed to reduce the exercise price of the Ex

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company") today announced that the Company received a delisting notice from The Nasdaq Stock Market LLC ("Nasdaq"). As previously disclosed in the Current Report on Form 8-K filed by the Company on November 25, 2025 with the Securities and Exchange Commission (the "SEC"), on November 19, 2025, the Company received notices from Nasdaq indicating that the Company's listed securities failed to comply with the $50,000,000 market value of listed securities (MVLS) requirement for continued listing in accordance with Nasdaq Listing Rule 5450(b)(2)(A) (the "MVLS Rule") and the $15,000,000

FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. ("Liminatus" or the "Company") today announced that it has entered into a definitive Merger Agreement dated May 17, 2026, with InnocsAI LLC ("InnocsAI"), a biotechnology company focused on advanced CAR-T and antibody-based oncology therapies. Under the terms of the Merger Agreement, InnocsAI will merge with and into a newly formed wholly owned Delaware subsidiary of Liminatus, with the subsidiary surviving as a wholly owned subsidiary of the Company. The transaction is intended to expand Liminatus' oncology pipeline with multiple biologic and cellular therapy assets designed to address significant challenges in hem

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

10-Q - Liminatus Pharma, Inc. (0001971387) (Filer)

10-K - Liminatus Pharma, Inc. (0001971387) (Filer)

CERRITOS, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Liminatus today announced plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody designed to engage innate immune pathways and complement established immuno-oncology therapies. IBA101 is engineered to target the CD47 "don't-eat-me" signal, a mechanism that enables tumor cells to evade innate immune surveillance. By enhancing macrophage-mediated tumor clearance and antigen presentation, IBA101 is designed to work alongside PD-1/PD-L1 checkpoint inhibitors, which remain the backbone of treatment across multiple solid tumor indications. The planned Phase 1 study is designed as a s

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

SCHEDULE 13G - Liminatus Pharma, Inc. (0001971387) (Subject)

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

424B4 - Liminatus Pharma, Inc. (0001971387) (Filer)

CERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company"), a pre-clinical stage immuno-oncology company developing next-generation CD47-blockade therapies, today announced the pricing of  its best-efforts public offering of 13,813,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per pre-funded warrant) and accompanying warrants. The warrants will have an exercise price of $0.29 per share, will be exercisable immediately upon issuance and will expire on the fifth anniversary

EFFECT - Liminatus Pharma, Inc. (0001971387) (Filer)

S-1 - Liminatus Pharma, Inc. (0001971387) (Filer)

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

10-Q - Liminatus Pharma, Inc. (0001971387) (Filer)

LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Understanding (MOU) with Capital Trust Group Limited (CTG), a New Zealand-based investment management firm, for a USD 30,000,000 equity financing via an earn-out mechanism to support Liminatus's research and development of advanced immunotherapy assets. Subject to completion of diligence and the negotiation of definitive agreements, CTG intends to subscribe to newly issued shares of Liminatus, subject to compliance with Nasdaq listing rules and U.S. sec

10-Q - Liminatus Pharma, Inc. (0001971387) (Filer)

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

3 - Liminatus Pharma, Inc. (0001971387) (Issuer)